Junior to adult onset
For autosomal dominant disorders, cats with one or two copies of the disease variant are at risk of developing the condition. Inheriting two copies of the risk variant may make the risk higher or the condition more severe. They may produce kittens affected with the disorder if bred.
At risk cats may show signs of this disease in their lifetime, although many will not develop the condition due to absence of additional risk factors.
Partner with your veterinarian to make a plan regarding your cat’s well-being, including any insights provided through genetic testing. If your pet is at risk or is showing signs of this disorder, then the first step is to speak with your veterinarian.
Hypertrophic Cardiomyopathy (HCM) is the most common cardiac disease in cats worldwide. The disorder is characterized by an increase in wall thickness of the left ventricle and the interventricular septum. This causes turbulence in blood flow and increased venous pressure in the left atrium and lungs, which may or may not coincide with a cardiac murmur upon auscultation. The clinical signs most commonly noted with the disease are respiratory signs associated with congestive heart failure such as tachypnea, exercise intolerance and panting, difficulty breathing, and (rarely) coughing. Thromboembolism may also occur and affected cats have an increased risk of sudden cardiac death. Clinical and echocardiographic signs classically appear after the cat has reached breeding age, as the most common age of diagnosis for HCM is five to seven years. Specifically in Ragdoll cats, however, the disease has an early onset with an average age of diagnosis being only fifteen months. In the Ragdoll, a point mutation (R820W) in the MYBPC3 gene has been found as causative for the disease. Cats with two copies of the mutation (homozygotes) have earlier onset and increased severity of the disease compared to those with only one copy of the mutation (heterozygotes). The mode of inheritance is autosomal dominant with incomplete penetrance.
Cats that are at risk for developing hypertrophic cardiomyopathy should be examined at least once a year by a veterinarian, preferably a cardiologist as HCM requires an echocardiogram (heart ultrasound) for definitive diagnosis and to understand the severity of the condition for the individual cat. As there is no curative treatment for the condition, therapy is guided to addressing disease sequelae. Clinical signs vary among affected cats and treatment should be optimized for the individual cat. Treatment options may include beta-blockers and medications for prevention of thrombi (clots). Should the disease progress to heart failure, medications for treatment of cardiac failure are indicated.
There are many responsibilities to consider when breeding cats. Regardless of test results it is important that your cat is in good general health and that you are in a position to care for the kittens if new responsible owners are not found. For first time or novice breeders, advice can be found at most cat registry websites.
This disease is autosomal dominant with incomplete penetrance meaning that one copy of the variant is needed for disease signs to occur, but the relative risk of disease development in cats with two copies of the variant is significantly higher than that for cats with one copy of the variant. Due to the high frequency of the HCM variant within the Ragdoll breed, cats with one copy of the disease variant can be considered for breeding with cats tested clear for the HCM variant in order to maintain genetic diversity within the breed. Approximately half of the kittens in a litter from this breeding will have no copies of the HCM variant and half will have one copy of the HCM variant with a relatively low risk of disease development. Please note: It is possible that disease signs similar to the ones caused by the HCM variant could develop due to a different genetic or clinical cause.
All coordinates reference FelCat9.0
Meurs, K. M., Norgard, M. M., Ederer, M. M., Hendrix, K. P., & Kittleson, M. D. (2007). A substitution mutation in the myosin binding protein C gene in ragdoll hypertrophic cardiomyopathy. Genomics, 90(2), 261–264. View the article